Evaluation of the pro-inflammatory potential of nanostructured drug carriers in knee-joints of rats: Effect on nociception, edema, and cell migration

Journal of Pharmaceutical Sciences

Volumn 98, Issue 12, 2009, Pages 4844-4851

  De Faria, Tatiany Jovita ^a   Souza Silva, Eduardo ^a   De Oliveira, Daniel Teixeira ^a   Senna, Elenara Lemos ^a   Tonussi, Carlos Rogério ^a  

^a FEDERAL UNIVERSITY OF SANTA CATARINA   (Brazil)

Author keywords

Arthritis; Drug delivery; Inflammatory pain; Nanocarrier; Nanoparticle

Indexed keywords

CARRAGEENAN; NANOMATERIAL; POLYGLACTIN; SOLID LIPID NANOPARTICLE;

ANIMAL CELL; ANIMAL EXPERIMENT; ARTICLE; CELL MIGRATION; CONTROLLED STUDY; FEMALE; KNEE; LEUKOCYTE; NOCICEPTION; NONHUMAN; PARTICLE SIZE; PAW EDEMA; RAT; SYNOVIOCYTE; ZETA POTENTIAL;

EID: 71649103794     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21788     Document Type: Article

References (26)

1. Lemarchand C, Gref R, Couvreur P. 2004. Targeting drug delivery in cancer therapy. Eur J Pharm Biopharm 58:327-341.
2. Vasir JK, Labhasetwar V. 2005. Targeted drug delivery in cancer therapy. Technol Cancer Res Treat 4:363-374. (Pubitemid 41242611)
3. Yih TC, Al-Fandi M. 2006. Engineered nanoparticles as precise drug delivery systems. J Cell Biochem 97:1184-1190.
4. Velez G, Yuan P, Sung C, Tansey G, Reed GF, Chin CC, Nussenblatt RB, Robinson MR. 2002. Pharmacokinetics and toxicity of intravitreal chemotherapy for primary ocular lymphoma. Arch Ophthalmol 45:416-422. (Pubitemid 32963258)
5. Panyam J, Labhasetwar V. 2003. Biodegradable nanoparticles for drug and gene delivery to cells and tissue. Adv Drug Deliv Rev 55:329-347. (Pubitemid 36297053)
6. Müller RH, Radtke M, Wissing SA. 2002. Nanostructured lipid matrices for improved microencapsulation of drugs. Int J Pharm 21:121-128. (Pubitemid 34899443)
7. Mehnert W, Mäder K. 2001. Solid lipid nanoparticles: Production, characterization and applications. Adv Drug Deliv Rev 47:165-196. (Pubitemid 32324113)
8. Ziats NP, Miller KM, Anderson JM. 1988. In vitro and in vivo interactions of cells with biomaterials. Biomaterials 9:5-13.
9. Fernández-Urrusuno R, Fattal E, Porquet D, Féger J, Couvreur P. 1995. Influence of surface properties on the inflammatory response to polymeric nanoparticles. Pharm Res 12:1385-1387.
10. Bazile D, Prud'homme C, Dassoulet MT, Marlad M, Spenlehauer G, Veillard M. 1995. Stealth Me-PEG-PLA nanoparticles avoid uptake by the mononuclear phagocytes system. Int J Pharm 84:493-498.
11. Gref R, Luck M, Quellec P, Marchand M, Dellacherie E, Harnisch S, Blunck T, Muller RH. 2000. Stealth corona-core nanoparticles surface modified by polyethyleneglycol (PEG): Influences of the corona (PEG chain length and surface density) and core composition on phagocytic uptake and plasma protein adsorption. Colloids Surf B Biointerfaces 18:301-313. (Pubitemid 30479870)
12. Shukla R, Bansal V, Chaudhary M, Basu A, Bhonde RR, Sastry M. 2005. Biocompatibility of gold nanoparticles and their endocytotic fate inside the cellular compartment: A microscopic overview. Langmuir 23:10644-10654.
13. Bansal SS, Joshi A, Bansal AK. 2007. New dosage formulations for targeted delivery of cyclo-oxygenase-2 inhibitors: Focus on use in the elderly. Drugs Aging 24:441-451. (Pubitemid 46974911)
14. Fessi H, Puisieux F, Devissaguet JP, Ammoury N, Benita S. 1989. Nanocapsule formation by interfacial polymer deposition following solvent displacement. Int J Pharm 55:R1-R4. (Pubitemid 19247505)
15. Faria TJ, Campos AM, Lemos-Senna E. 2005. Preparation and characterization of poly (D,L-lactide) (PLA) and poly (D,L-lactide)-poly (ethyleneglycol) (PLA-PEG) nanocapsules containing antitumoral agent methotrexate. Mac Symp 229:228-233.
16. IASP (International Association for the Study of Pain). 1983. Ethical guidelines for investigation of experimental pain in conscious animals. Pain 16:109-110.
17. Müller RH, Mehnert W, Lucks JS, Schwarz C, zur Mühlen A, Weyhers H, Freitas C, Rühl D, 1995. Solid lipid nanoparticles (SLN) - An alternative colloidal carrier system for controlled drug delivery. Eur J Pharm Biopharm 41:62-69.
18. Tonussi CR, Ferreira SH. 1992. Rat knee-joint carrageenan incapacitation test: An objective screen for central and peripheral analgesics. Pain 48:421-427.
19. Tonussi CR, Ferreira SH. 1999. Tumour necrosis factor-α mediates carrageenan-induced knee-joint incapacitation and also triggers overt nociception in previously inflamed rat knee-joints. Pain 82:81-87.
20. Bressan E, Cunha FQ, Tonussi CR. 2006. Contribution of TNFalpha, IL-1beta and CINC-1 for articular incapacitation, edema and cell migration in a model of LPS-induced reactive arthritis. Cytokine 36:83. (Pubitemid 46049025)
21. Jiang J, Oberdorster G, Biswas P. 2009. Characterization of size, surface charge, and agglomeration state of nanoparticles dispersions for toxicological studies. J Nanopart Res 11:77-89.
22. Mosqueira VC, Legrand P, Pinto-Alphandary H, Puisieux F, Barrat G. 1999. Poly(D,L-lactide) nanocapsules prepared by a solvent displacement process: Influence of the composition on physicochemical and structural properties. Int J Pharm 89:614-626. (Pubitemid 30692832)
23. Loch-Neckel G, Nemen D, Puhl AC, Fernandes D, Stimamiglio MA, Alvarez Silva M, Hangai M, Santos Silva MC, Lemos-Senna E. 2007. Stealth and non-stealth nanocapsules containing camptothecin: In-vitro and in-vivo activity on B16-F10 melanoma. J Pharm Pharmacol 59:1359-1364. (Pubitemid 47606450)
24. Gref R, Domb A, Quellec P, Blunck T, Muller RH, Muller RH, Verbavatz JM, Langer R. 1995. The controlled intravenous delivery of drugs using PEG-coated sterically stabilized nanospheres. Adv Drug Del Rev 16:215-223.
25. Bocca C, Caputo O, Cavalli R, Gabriel L, Maglietta A, Gasco MA. 1998. Phagocytic uptake of fluorescent stealth and non-stealth solid lipid nanoparticles. Int J Pharm 175:185-193. (Pubitemid 28517974)
26. Schäfer-Korting M, Mehnert W, Korting HC. 2007. Lipid nanoparticles for improved topical application of drugs for skin diseases. Adv Drug Deliv Rev 59:427-443. (Pubitemid 47259224)